Pfizer recommends shareholders reject the below-market mini-tender offer by TRC Capital Investment Corporation
Pfizer Inc. (NYSE: PFE) announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 4 million shares of Pfizer common stock at a price of $27.35 per share in cash. TRC Capital Investment's offer price of $27.35 per share is approximately 4.4 percent lower than the $28.61 closing share price of Pfizer's common stock on December 27, 2023 - the business day prior to the date of the offer. (Source: World Pharma News)
Source: World Pharma News - January 18, 2024 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
‘Medicine is going personalised’: Moderna’s UK boss on the coming vaccine revolution
Darius Hughes was a key figure in Pfizer ’s pioneering Covid vaccine drive. Now he has changed companies – and sees a big future for mRNA technologyThe man who launched Pfizer ’s Covid-19 vaccine in the UK three years ago – when 90-year-old Margaret Keenan in Coventry becamethe first person in the world to receive one– is now overseeing the construction of a manufacturing and research centre in Oxfordshire for rival US jab maker Moderna.The company ’s Harwell site isBritain ’s first centre dedicated to the production of messenger RNA (mRNA) vaccines against new Covid variants and other illnesses, and part of ...
Source: Guardian Unlimited Science - January 16, 2024 Category: Science Authors: Julia Kollewe Tags: Pharmaceuticals industry Vaccines and immunisation Coronavirus Pfizer Business Health Infectious diseases Medical research Science Society UK news Cancer Source Type: news
Pfizer ’s Bourla Bets His Pension on Company Stock as CEO Defends Drug Firm
DAVOS, Switzerland—Albert Bourla has ambitious plans to turn around the situation at Pfizer. The market will decide if talk is cheap, but at least for now the stock looks cheap, or so the biopharma CEO wants investors to believe. And he put his money where his mouth is.#davos #switzerland #albertbourla #pfizer (Source: Reuters: Health)
Source: Reuters: Health - January 16, 2024 Category: Consumer Health News Source Type: news
Today ’s top business headlines: Peacock’s viewership win, dashed hopes for a moon landing, and increasing piracy rates
Wild Card game breaks streaming records: On Saturday, the Kansas City Chiefs and Miami Dolphins played in the AFC Wild Card game, garnering 27.6 million viewers, according to Nielsen—making it the United States’ most-streamed live event ever. Some fans expressed frustration that the game was…#kansascitychiefs #miamidolphins #afcwildcard #peacock #venture #section1981 #civilrightsact #fearlessfund #nonblack #pfizer (Source: Reuters: Health)
Source: Reuters: Health - January 16, 2024 Category: Consumer Health News Source Type: news
DEI opponents using a 1866 Civil Rights law to challenge equity policies in the workplace
NEW YORK — Opponents of workplace diversity programs are increasingly banking on a section of the Civil Rights Act of 1866 to challenge equity policies as well as funding to minority-owned businesses. Section 1981 of the act was originally meant to protect formerly enslaved people — or black…#civilrightsact #section1981 #edwardblum #fearlessfund #fearlessfunds #pfizer #supremecourts #alphonsodavid #1866civilrightsact #randolphmclaughlin (Source: Reuters: Health)
Source: Reuters: Health - January 15, 2024 Category: Consumer Health News Source Type: news
7 Incredible Reasons to Buy Pfizer Stock Right Now
Last year, pharmaceutical giant Pfizer (NYSE: PFE) encountered several issues, none more significant than the massive drop in revenue and earnings it experienced due to a shrinking coronavirus market. Investors reacted by selling off the stock, leading to a catastrophic performance for the…#pfe #pfizer #fda #albertbourla #seagen #prosperjuniorbakiny #motleyfool #buypfizerstock (Source: Reuters: Health)
Source: Reuters: Health - January 13, 2024 Category: Consumer Health News Source Type: news
PumasAI Maintains Strong Growth Trajectory with New Product Engineering and Pharmacometrics Hires from JuliaHub and Pfizer
Dr. Andreas Noack, a luminary in product engineering, joins PumasAI as the Head of Product Engineering, and Dr. Jessica Wojciechowski, an esteemed expert in clinical pharmacology and pharmacometrics, will be joining the team as the Director of Clinical Pharmacology and Pharmacometrics.... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 12, 2024 Category: Pharmaceuticals Tags: PER Source Type: news
The New Vaccines to Get in 2024
The U.S. Centers for Disease Control and Prevention (CDC) is recommending new vaccines for adults and kids in 2024, according to its latest annual guidelines finalized Jan. 11. The CDC’s Advisory Committee on Immunization Practices (ACIP), a collection of medical and public-health experts who regularly review evidence and research about vaccines, compiled the new guidelines.
[time-brightcove not-tgx=”true”]
Like it does every year, ACIP recommends that American adults receive an annual flu shot and several standard vaccinations, such as those for chickenpox (if they haven’t had it already) and ...
Source: TIME: Health - January 11, 2024 Category: Consumer Health News Authors: Haley Weiss Tags: Uncategorized healthscienceclimate Source Type: news
Mauritius: Bilateral Relations - Mauritius Receives New Batch of Bivalent Pfizer Vaccines
[Government of Mauritius] Mauritius received a new batch of Bivalent Pfizer vaccines from the United States of America to help counter the spread of COVID-19 pandemic and to protect the well-being of the population. The donation ceremony was held in presence of the Minister of Foreign Affairs, Regional Integration and International Trade, Mr Maneesh Gobin, and the Minister of Health and Wellness, Dr Kailesh Kumar Singh Jagutpal, this afternoon, at the Sir Harilal Vaghjee Memorial Hall in Port Louis. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 11, 2024 Category: African Health Tags: Coronavirus East Africa Health and Medicine Mauritius Source Type: news
Drugmakers Plot Way Into Obesity Market With Deals and Development Drugmakers Plot Way Into Obesity Market With Deals and Development
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will...Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 11, 2024 Category: Consumer Health News Tags: Diabetes & Endocrinology Source Type: news
Weight Loss Drug Windfall Attracts Pharma Companies Weight Loss Drug Windfall Attracts Pharma Companies
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will...Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 11, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news
Ultromics inks deal with Pfizer to develop AI technology
U.K. software developer Ultromics has entered an agreement with Pfizer to expedite marketing clearance in the U.S. for its AI algorithm for detecting cardiac amyloidosis.
Under the partnership with Pfizer, Ultromics will research and pursue U.S. Food and Drug Administration (FDA) clearance for its EchoGo Amyloidosis algorithm. The software has already received Breakthrough Device designation from the FDA for the detection of cardiac amyloidosis. The algorithm uses deep learning to analyze routine ultrasound scans of the heart (echocardiograms) to detect disease that often goes undetected during standard assessments, Ultro...
Source: AuntMinnie.com Headlines - January 10, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Ultrasound Source Type: news
TIVDAK ® supplemental Biologics License Application accepted for Priority Review by FDA for patients with recurrent or metastatic cervical cancer
Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of TIVDAK® (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy. (Source: World Pharma News)
Source: World Pharma News - January 10, 2024 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Your Path to Wealth: 3 Stocks Predicted to Double Your Investment by 2025
Today, identifying investments with promising growth potential is a quest every investor undertakes. Within the loud noises of the stock market, three standout companies are making waves. Their strategies and innovations forecast substantial gains, promising a 2X capital level by 2025. The first…#paypal #paypalwallet #apple #google #pfizer #pfe #yoy #moderna #spikevax #yianniszourmpanos (Source: Reuters: Health)
Source: Reuters: Health - January 10, 2024 Category: Consumer Health News Source Type: news
Pfizer to remain aggressive on obesity market after setback
Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday. "Pfizer's position is that we believe that obesity is a place…#pfizer #albertbourla #jpmorgan #elililly #mounjaro #novonordisk #glp1 #novoozempic #seagen #rsv (Source: Reuters: Health)
Source: Reuters: Health - January 9, 2024 Category: Consumer Health News Source Type: news
